Pomerantz LLP Investigates Claims Against Ultragenyx Pharmaceutical Inc.

Pomerantz LLP is investigating claims on behalf of investors of Ultragenyx Pharmaceutical Inc. alleging securities fraud or unlawful business practices. The investigation concerns a Phase 3 study of UX143 for osteogenesis imperfecta. Investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980.

Pomerantz LLP, a leading firm in corporate, securities, and antitrust class litigation, has initiated an investigation on behalf of investors of Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE). The investigation centers around allegations of securities fraud or unlawful business practices by Ultragenyx and certain of its officers and/or directors.

The investigation was sparked by a press release issued by Ultragenyx and its development partner, Mereo BioPharma Group plc, on July 9, 2025. The release announced that the randomized, placebo-controlled Phase 3 portion of the Orbit study evaluating UX143 (setrusumab) in pediatric and young adult patients with osteogenesis imperfecta (OI) was progressing toward a final analysis. The Data Monitoring Committee meeting advised that the final analysis would occur around the end of the year.

Following this announcement, Ultragenyx's stock price experienced a significant drop. On July 10, 2025, the stock fell by $10.41 per share, or 25.11%, closing at $31.04 per share.

Investors affected by this situation are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980, for more information about joining the class action.

Pomerantz LLP has a long-standing reputation for fighting for the rights of victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The firm has recovered numerous multimillion-dollar damages awards on behalf of class members.

References:
[1] https://www.morningstar.com/news/globe-newswire/9519210/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ultragenyx-pharmaceutical-inc-rare
[2] https://www.prnewswire.com/news-releases/investor-alert-pomerantz-law-firm-investigates-claims-on-behalf-of-investors-of-ultragenyx-pharmaceutical-inc---rare-302538525.html